NCT06357754Recruiting
Transgene Assay Testing Service of Tumor Samples From Patients Who Received a Bristol-Myers Squibb Manufactured Gene Modified Cell Therapy and Have a Qualifying Second Primary Malignancy
Summary
The purpose of this transgene assay testing service is to evaluate tumor samples for transgene levels in patients who received a commercially available Bristol-Myers Squibb manufactured gene modified cellular therapy and have reported a qualifying second malignancy.
Inclusion criteria
• Participant has received a commercially available Bristol-Myers Squibb (BMS) manufactured Gene Modified Cell Therapy (GMCT) and has been diagnosed with a qualifying second primary malignancy or a second primary malignancy which BMS has qualified for testing. • Participant has received a commercially available BMS manufactured GMCT in a clinical trial or other investigational setting (including non-conforming product) for which there is no testing protocol in place for that trial or investigational setting and has been diagnosed with a qualifying second primary malignancy or a second primary malignancy which BMS has qualified for testing.
Exclusion criteria
• Participant is actively participating in a clinical trial where information and sample collection is being conducted under that clinical trial. • Participant has not received a BMS manufactured GMCT or has not been diagnosed with a qualifying second primary malignancy.
Contacts
The trial team's contact details are shown on request.
See the official trial record- Status
- Recruiting
- Phase
- —
- Study type
- Observational
- Countries
- Switzerland, Germany, United States, Japan
- Sponsor
- Bristol-Myers Squibb(Industry)
- Protocol no.
- CA082-085
- Conditions
- Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukaemia, Multiple Myeloma
- Interventions
- Biological
Treatments studied
- Idecabtagene vicleucel
- Lisocabtagene maraleucel
Locations · 5
- Aarau, SwitzerlandKantonsspital AarauRecruiting at this site
- Essen, GermanyUniversitaetsklinikum Essen (AoR)Recruiting at this site
- Dallas, United StatesUt SouthwesternRecruiting at this site
- Salt Lake City, United StatesHuntsman Cancer Institute at the University of UtahRecruiting at this site
- Toyokawa, JapanToyokawa City HospitalRecruiting at this site
In total, worldwide, 5 of the 8 sites listed in the registry are recruiting; the other 3 are not currently recruiting.
Site status per the ClinicalTrials.gov registry (last update posted: January 22, 2026).
This status may have changed and says nothing about your eligibility: before taking any step, check with your oncologist or the site.
See also
Other versions
These results are indicative and do not replace medical advice — discuss them with your doctor.